- OpenAI launched a free, purpose-built AI tool for verified U.S. healthcare professionals, offering clinical documentation, real-time cited research, workflow templates, and HIPAA compliance support.
- OpenAI is rapidly expanding its pharma footprint, with new strategic deals, adding to existing collaborations with Novo Nordisk, Eli Lilly, Sanofi, Moderna, and others, reflecting a booming healthcare AI market.
OpenAI has taken another step in the direction of what it calls ‘making AI better for clinicians.’ On April 22, 2026, the AI stalwart unveiled ChatGPT for Clinicians, a purpose-built version of its flagship AI assistant designed to support a range of healthcare workflows. These include clinical documentation, medical research, and patient care consultations. The tool is being offered for free to verified physicians, nurse practitioners, physician assistants, and pharmacists practicing in the U.S.
As part of its international expansion strategy, the company is expected to work with the Better Evidence Network to pilot clinician access beyond U.S. borders, subject to local regulatory requirements.
The launch is well-timed as physician use of AI has reached an all-time high. According to a 2026 survey by the American Medical Association, over 80% of respondents are now using AI in a professional capacity. This is more than double the figure recorded in 2023.
What the Tool Offers
ChatGPT for Clinicians is built around several core capabilities. Clinicians will have access to OpenAI’s most advanced frontier models for complex healthcare queries, designed to handle clinical questions, documentation, and research with greater reliability. The platform also enables users to build reusable workflow templates for recurring tasks such as referral letters, prior authorization requests, and patient instructions.
On the research side, the tool provides real-time, cited answers drawn from peer-reviewed medical literature, allowing clinicians to reason through cases faster. It also supports in-depth literature reviews, enabling users to delegate comprehensive research tasks and receive well-cited reports within minutes. For cases involving patient health information, HIPAA compliance support is available through a Business Associate Agreement for qualifying accounts. The platform also includes multi-factor authentication and a policy of not using conversations to train its models.
AI Partnerships: A Fixture in the Life Sciences Industry
OpenAI’s pursuit of healthcare AI is not new. Just a week ago, the company introduced GPT-Rosalind, its first dedicated model for the life sciences sector. The model is designed to support research across biology, drug discovery, and translational medicine, and is optimized for scientific workflows that include evidence synthesis, hypothesis generation, experimental planning, and multi-step research tasks.
The impetus behind the model is the stubborn inefficiency of pharmaceutical development timelines. It takes between 10 and 15 years to move from target discovery to regulatory approval for a new drug in the U.S. Gains made at the earliest stages of discovery compound downstream in better target selection, stronger biological hypotheses, and higher-quality experiments.
Following the track, OpenAI has also announced a strategic partnership with Danish pharmaceutical giant Novo Nordisk. The collaboration will enable Novo Nordisk to harness AI to analyze complex datasets, identify promising new drug candidates, and shorten the journey from research to patient access. Beyond research and development, the partnership will extend into manufacturing, supply chain, and commercial operations, with pilot programs expected to begin by the end of 2026.
The tie-up adds Novo Nordisk to a growing list of major pharmaceutical companies partnering with OpenAI. Eli Lilly collaborated with the company in 2024 to discover novel medicines targeting drug-resistant bacteria, while Sanofi and Formation Bio have an OpenAI pact focused on clinical trial enrolment. Moderna also has a wide-ranging initiative running with the company.
Such activities reflect a broader and intensifying strategic push by AI firms into the healthcare and life sciences sector, driven by both the scale of the opportunity and the transformative potential of the technology.
